PageHeader

OUR LATEST INNOVATIONS

Introducing OswaldRx Plus: An Innovative Pharmacy Benefits Solution for Employers

CLEVELAND – Feb. 3, 2020 –  Oswald Labs introduces OswaldRx Plus, a proprietary solution focused on optimizing pharmacy programs by providing access to the clinical expertise of dedicated pharmacists. OswaldRx Plus helps members actively manage their medications while supporting employers to reduce cost and control risk for their population.

“The OswaldRx Plus pharmacy program leverages cutting edge technology to provide a deep dive analysis into all aspects of the pharmacy contract, enabling our clients to secure market leading pricing terms and financial results,” said Scott Bizjak, VP, Director Agency Services at Oswald Companies.

“While “Transparency” and “Pass Thru” agreements remain components to a successful pharmacy program, they do not necessarily on their own result in the lowest net cost strategy. Our new OswaldRx Plus program takes this a step further by adding customized clinical and pharmacist support to deliver best-in-class quality and value,” said Bill Fisher, SVP, Practice Leader, Middle Market Group Benefits at Oswald Companies.

Key features include:

  • Dedicated team of pharmacists
  • Specialty cost optimization
  • Patient assistance navigation
  • Medication therapy management
  • Formulary customization and management
  • Patient counseling

“Our partnership brings the focus of pharmaceutical savings to the human level. We advocate for our clients, delivering the best pricing and outcomes, while simultaneously providing exceptional, quality care for their employees,” said Luke Swintek, PharmD, Director, at New Era Rx.

Expert consultation, preferred partnerships, advanced technology and education allows OswaldRx Plus to deliver optimal pricing and contract terms with an exceptional member experience.

Oswald Labs Announces Exclusive Partnership With Regenexx to Reduce Orthopedic Surgical Spend for Employers

Oswald Labs is excited to announce a unique partnership with Regenexx to offer access to non-surgical orthopedic alternatives to Oswald Lab’s self-funded employer groups

CLEVELAND – March 1, 2020 –  Oswald Labs, a cooperative effort of Oswald Companies and Spark360 designed to bring purposeful, positive disruption to the insurance sector through innovation, collaboration and experimentation, has partnered with Regenexx, a network of leading interventional orthopedics clinics. The partnership allows Oswald Companies to offer its clients Regenexx procedures, which effectively intervene on 70 percent of elective orthopedic injuries and conditions where surgery was previously the only solution*.

“We are proud to present our clients and self-funded employers with a new technology transforming orthopedic care and driving down costs,” said Bill Fisher, SVP, Practice Leader, Group Benefits at Oswald Companies.

Regenexx procedures involve precise injections of custom orthobiologics to treat approximately 40 orthopedic conditions. This interventional approach enables employers to save up to 70 percent of orthopedic costs depending on the procedure, while reducing absenteeism and increasing employee satisfaction, all while reducing the number of unnecessary orthopedic surgeries performed annually.

“Regenexx is looking forward to expanding our mission of producing the best possible patient outcomes for Oswald Companies and their clients through our innovative alternative to orthopedic surgery,” said Regenexx CEO Jason Hellickson. “Overuse and misuse of orthopedic surgery is prevalent in our health care system today. Our patented protocol to treating common orthopedic conditions is transforming the care pathway of an orthopedic patient who can now avoid a surgical encounter with less risk and less downtime.”

Watch a short video about Regenexx here.

*This applies only to elective orthopedic surgery without fracture-related care and acute care trauma.